- Home
- AMAT vs AMGN Comparison
AMAT vs AMGN Comparison
Compare AMAT & AMGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMAT
- AMGN
- Stock Information
- Founded
- AMAT 1967
- AMGN 1980
- Country
- AMAT United States
- AMGN United States
- Employees
- AMAT N/A
- AMGN N/A
- Industry
- AMAT Semiconductors
- AMGN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AMAT Technology
- AMGN Health Care
- Exchange
- AMAT Nasdaq
- AMGN Nasdaq
- Market Cap
- AMAT 151.9B
- AMGN 147.3B
- IPO Year
- AMAT N/A
- AMGN N/A
- Fundamental
- Price
- AMAT $163.59
- AMGN $263.38
- Analyst Decision
- AMAT Buy
- AMGN Buy
- Analyst Count
- AMAT 21
- AMGN 22
- Target Price
- AMAT $218.14
- AMGN $329.05
- AVG Volume (30 Days)
- AMAT 6.8M
- AMGN 4.7M
- Earning Date
- AMAT 02-13-2025
- AMGN 02-04-2025
- Dividend Yield
- AMAT 0.98%
- AMGN 3.62%
- EPS Growth
- AMAT 6.17
- AMGN N/A
- EPS
- AMAT 8.61
- AMGN 7.83
- Revenue
- AMAT $27,176,000,000.00
- AMGN $32,534,000,000.00
- Revenue This Year
- AMAT $10.75
- AMGN $20.04
- Revenue Next Year
- AMAT $8.81
- AMGN $3.41
- P/E Ratio
- AMAT $19.00
- AMGN $33.62
- Revenue Growth
- AMAT 2.49
- AMGN 21.25
- 52 Week Low
- AMAT $148.05
- AMGN $253.30
- 52 Week High
- AMAT $255.89
- AMGN $346.85
- Technical
- Relative Strength Index (RSI)
- AMAT 36.99
- AMGN 31.29
- Support Level
- AMAT $166.81
- AMGN $253.30
- Resistance Level
- AMAT $174.43
- AMGN $280.00
- Average True Range (ATR)
- AMAT 4.66
- AMGN 5.95
- MACD
- AMAT -0.60
- AMGN -0.21
- Stochastic Oscillator
- AMAT 17.32
- AMGN 35.90
About AMAT Applied Materials Inc.
Applied Materials is the largest semiconductor wafer fabrication equipment, or WFE, manufacturer in the world. Applied Materials has a broad portfolio spanning nearly every corner of the WFE ecosystem. Specifically, Applied Materials holds a market share leadership position in deposition, which entails the layering of new materials on semiconductor wafers. It is more exposed to general-purpose logic chips made at integrated device manufacturers and foundries. It counts the largest chipmakers in the world as customers, including TSMC, Intel, and Samsung.
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.